deprenyl was proven using numerous in vitro and in vivo models (Tatton et al., 1994; Magyar et al., 1998; Magyar et al., 2004; Tatton, 2000; Tatton et al., 2002; Szende et al., 2000; Szende et al., 2001) .
Estrogen is one of the hormones that regulate numerous functions of many tissues by its transcriptionmodulatory action. Neuroprotective effect of estrogen and the selective estrogen receptor modulators (SERM) in cases of brain damage of various origin resulting in neurodegenerative and cognitive disorders is well known (Behl, 2002; Liu et al., 2010 , Brann et al., 2007 but its molecular mechanism has still not been clarified. The aim of our presented investigations was to study the cytoprotective effect of (-)-deprenyl in vitro cultured non-neuroectodermal cell lines. At the same time by applying the estrogen-dependent cell line (MCF-7) the possible estrogen receptor activating property of (-)-deprenyl could be studied.
MATERIALS AND METHODS 2.1. Cell Cultures and Growth Conditions
The experiments were carried out on estrogen receptor positive (ER+) HepG2 (ECACC 85011430) human liver carcinoma and on ER+ MCF-7 (ECACC 86012803) human breast carcinoma cell lines. The cells were cultured in a humified 5% CO2 thermostat at 37 o C in Dulbecco's medium (DMEM) complemented with 10% heat-inactivated fetal calf serum (FCS), L-glutamine, and penicillinstreptomycin.
(-)-Deprenyl, 17-estradiol (E2), ICI 182,780 (ICI), MTT reagents were from Sigma-Aldrich Co. (St. Louis, USA), the nutrient media DMEM, trypsin-EDTA solution, PBS, L-glutamine and fetal bovine serum from Invitrogen Gibco Ltd. (UK), culture dishes were from Nunc (Thermo Fisher Scientific, Inc., Denmark).
Treatment
For cell cycle studies and ER activation experiments 106 cells were seeded in 100 mm Petri dishes and treatments were applied after 24 h of pre-incubation. Cells were kept in serum-free condition for three days to induce apoptosis and at 72 h substances being tested (E2, ICI 182,780, (-)-deprenyl) were added for further 24 and 48 hrs. Experiments were repeated three times and three parallel dishes were used for each concentration. Controls were kept in serum-free DMEM.
MTT Viability Assay
Cytotoxic effects on the growth and viability of 2 x 104 cell/ml were determined in 96-microwell plates using tetrazolium dye MTT (3[4,5-di-methylthiazol-2-yl]-2,5-diphenyltetrasolium bromide) assay, as described (Mosmann, 1983; Horiuchi et al., 1988; Cory et al., 1991; Kocsis et al,. 2005 ). Optical density (O.D.) of the wells was determined using an Anthos 2020 (Salzburg, Austria) enzyme-linked immunosorbent assay (ELISA) microplate reader at a test wavelength of 570 nm and a reference wavelength of 690 nm. All MTT experiments were performed at least three times with four parallel wells for each concentration in the range of 0.1 pM to 100 µM of (-)-deprenyl. The control cells were grown under the same conditions without the addition of the test compounds. Cell survival (%of control) was calculated relative to untreated controls.
Chemiluminescent Measurement of Total Scavenger Capacity
96 well cell culture plates were used for the measurement of antioxidant capacity plating 3000 HepG2 cells per well. The total scavenger capacity of 0.1 pM to 100 µM (-)-deprenyl on HepG2 cell cultures was detected by chemiluminometric method in the H2O2:OH•-luminol-microperoxidase system using a Total Scavanger Capacity (chemiluminometric) kit of Diachem Ltd. (Budapest) (Blázovics et al., 1999 ) and a Victor3 multilabel reader (PerkinElmer, Waltham, MA, USA). Wallac 1420 software (PerkinElmer-Wallac, Turku, Finland) was used for data analysis. The intensity of the emitted light is proportional to the amount of free radicals present in the reaction. In the presence of scavenger compounds the intensity of the measurable light declines depending on the concentration of free radicals.
(-)-Deprenyl was applied to HepG2 cell cultures in the final concentration of 0.1 pM, 1 pM, 10 pM, 100 pM, 1 nM, 10 nM, 100 nM, 1 μM, 10 μΜ, 20 μΜ and 30 μM for 24 hrs. The total scavenger capacity was determined by using Diachem kit and luminescence values were read by Victor3 multilabel reader (Perkin-Elmer) in luminometry mode and data were analyzed by Wallac 1420 (Perkin-Elmer) software (Hagymási et al., 2001).
Flow Cytometry
HepG2 and MCF-7 cells were cultured for 24 hrs in 100 mm Petri dishes at an initial plating density of 1x106 cells/dish in DMEM containing 10% FBS and antibiotics. After 24 hrs the media was changed to serum-free DMEM to induce apoptosis. 72 hrs following serum deprivation cells were treated with (-)-deprenyl in the concentration range of 0.1 nM to 10 µM for 24 and 48 hours. Pulse labeling of cells with 5 mg/ml 5-bromo-2-deoxyuridine (BrdU, Sigma) was performed 2 h prior to the termination of the cultures. For the determination of the cell cycle phases, DNA was stained with propidium iodide (PI) and the incorporated BrdU was detected immunocytochemically with FITC-labeled anti-BrdU monoclonal antibodies (Becton Dickinson, USA). DNA denaturation prior to PI and FITC-anti-BrdU staining was performed at room temperature using a modification of the method described by van Erp et al. (1988) . The cells were analyzed by flow cytometry in a FACSCalibur (Becton Dickinson, USA) system at a flow rate of approximately 400 cells/s. CellQuest software (Becton Dickinson, USA) was used for data analysis. The percentages of apoptotic fractions were determined on the basis of PI and anti-BrdU-FITC/PI fluorescence.
Measurement of Estrogen Receptor Activation in MCF-7 Cells
106 MCF-7 human breast adenocarcinoma-derived cells were plated in 100 mm Petri dishes and precultured in 5% FCS completed DMEM in humified CO2 incubator at 37oC for 24 h. After the pre-incubation period (-)-deprenyl was added in the concentration series of 10 nM, 100 nM, 1 μΜ 10 μM and 100 μΜ for 24 h. 1 nM 17- estradiol and 10 nM of the estrogen receptor antagonist ICI were applied as positive and negative controls. ICI was applied simultaneously with all doses of (-)-deprenyl as well as with 17- estradiol in order to confirm that the effects were mediated by ER. At the end of the 24 h of treatment total RNA was isolated using the GenElute total RNA isolation kit (Sigma, RTN70) following the manufacturer's instructions. Reverse transcription was performed in 20 µl reaction volumes, using 1 µl of isolated total RNA, 0.1 µg/ml oligo-dT12-18 primer (for transcription of mRNAs) and 500 nM 18S-ribosomal RNA (rRNA) specific reverse primer (for transcription of 18S ribosomal RNA used as internal control, see below the sequences) ( Estrogen-receptor activity was monitored by the trefoil factor (PS2, presenilin 2) transcript formation. The pS2 gene has an estrogen-responsive element (ERE) in its promoter, so the amount of transcribed pS2 mRNA is proportional to the activity of ER (Knowlden et al., 1997) . In the PCR reactions, parallel amplification of 18S rRNA was performed as an internal control (Schmittgen et al., 2000) . The pS2-specific primers used were 5'CATGGAGAACAAGGTGATCTG3' and 5'CAGAAGCGTG TCTGAGGTGTC3' amplifying 336 bp DNA and 18S-rRNA primers were 5'GTAACCCGTTG AACCCCATT3' and 5'CCATCCAATCGGTAGTAGCG3' producing 151 bp PCR fragment. Primers were synthesized by the Genodia Co. (Budapest, Hungary). The 20 µl PCR reaction volumes contained 1 µl 1st strand cDNA, 500 nM of each primers, 3 mM MgCl2 and 1xLightCycler DNA master SYBR Green I mix (Roche, Mannheim, Germany). Real-time PCR assays were performed in a LightCycler carousel-based system (Roche LC 1.2).
STATISTICAL ANALYSIS
Results were assessed by one-way analysis of variance (ANOVA) using GraphPad Prism (GraphPad Software, Inc., San Diego, CA, USA) Dunnett test application (all data were compared to the control) statistical analysis program. P values of p<0.05 were considered to be significant.
RESULTS

MTT Assay
Under non serum-deprived conditions (-)-deprenyl did not show any cytotoxic effect in either cell lines in the studied concentration range (up to 100 μM) (Fig 1. a and b ).
In the serum starvation experiments the high concentration of deprenyl (100 μM) caused significantly increased cell death compared to the non-treated controls in both MCF-7 and HepG2cell cultures (Figs 2 and 3). In case of HepG2 cell cultures with serum deprivation, low doses (0.1 nM -1 μΜ) of the (-)deprenyl showed a tendency of cytoprotective effect at 48 and 72 hrs, however, not at significant level, whereas no effect was found at 24 hrs ( Fig. 2 b and c) . Serum-starved MCF-7 cells at 48 and 72 hrs of (-)-deprenyl treatment in the concentration range of 1-100 nM exhibited a significant increase in viable cell population compared to the non-treated serum starved control.
Flow Cytometry
MCF-7 cells after 24 hrs serum-deprivation followed by treatment for 24 hrs intervals (-)-deprenyl at 1 nM, 100 nM and 1 μM concentration in serum-free medium showed a significantly reduced apopototic rate by flow cytometry compared the untreated control. 10μM concentration of (-)-deprenyl was cytotoxic in MTT assay (Fig. 2. a, b) . When the treatment interval was raised to 48 hrs the extent of apoptosis did not change at lower concentrations and increased significantly at higher concentration ( Fig. 4 A and B) while at low dosage the antiapoptotic effect was not detectable. HepG2 cell cultures after 24 hours serum-deprivation and consecutive treatment at 0.1 nM, 100 nM, 1 μM and 10 μM (-)-deprenyl concentrations for 24 and 48 hrs after the treatment in three sequential concentrations (1-100-1000 nM) exhibited significant antiapoptotic effect compared to the control. Similar effect was observed after 48 hrs treatment with higher doses (1-10 μΜ) ( Fig. 5 A and B ). 
Antioxidant Capacity
Estrogen Receptor Activation
(-)-Deprenyl at 1 M and 10 M concentration significantly induced the expression of the ER-regulated PS2 gene in MCF-7cells. 10 μM (-)-Deprenyl treatment significantly raised the pS2 gene expression up to the level caused by 1 nM 17β-estradiol used as positive control (Fig. 7) . The presence of the estrogen receptor blocker ICI inhibited the (-)-deprenyl-induced pS2 gene expression ( Fig. 7) .
DISCUSSION
The dose dependent apoptosis inhibiting effect of (-)-deprenyl has been studied primarily in neuroectodermal cells and tissues both in vitro and in vivo (Salo and Tatton, 1992; Tatton et al., 1994) . A few studies raised the possibility that the antiapoptotic effect is valid for tissues and cells of other histogenesis as well (Qin et al., 2003; Toronyi et al., 2002) .
Results in our present study prove that (-)-deprenyl influences apoptosis and cell proliferation not only in neuroectodermal cells.
The anti-apoptotic effect of (-)-deprenyl depends on dose, cell type, culture conditions, longer or shorter serum deprivation and treatment time. The cell viability of non-starved HepG2 and MCF-7 cultures treated with (-)-deprenyl in the 0.1 pM-100 μM dose range did not decline. In fact, rather there was a slight, non-significant, rise in the population of viable cells.
Following serum deprivation, cultures treated with higher (10-100 μM) concentration of (-)-deprenyl showed a significant decline in viability compared to the untreated control whereas low concentrations (1 nM-100 nM) of (-)-deprenyl caused a significant viability increase in MCF-7 cell cultures after longer (48 and 72 hrs) treatment. HepG2 cell cultures reacted the same way to deprenyl treatment as MCF-7 but changes in viability were moderate and not significant. The cytotoxic effect of 100µM (-)-deprenyl was significant on both cell lines.
Changes in viability were reflected by changes in apoptotic ratio, as well. Our experiments prove that the cytoprotective effect of (-)-deprenyl extends not only to cells of CNS origin but also on other somatic cells, endorsing the possibility that the antiapoptotic effect of (-)-deprenyl is not based on MAO-B inhibition but rather on the stabilization of mitochondrial membranes or inhibiting the apoptotic pathway The anti-apoptotic property of (-)-deprenyl may have a favorable effect against cell death caused by hypoxia-reperfusion in various tissues and organs like heart muscle, arterial endothel, brain or kidney. At the same time reduced apoptotic activity may be accompanied by cell proliferation enhancing regenerative processes. With respect to this, as found in our earlier investigations, the anti-apoptotic and proliferative processes induced by (-)-deprenyl may not effect tumors of neuroectodermal origin as prolonged (-)-deprenyl application does not lead to elevated tumor progression (Magyar et al., 1998) .
In the case of Parkinson's disease the nigrostriatal dopaminergic lesion can be attributed to increased hydrogen peroxide, superoxide and hydroxyl radicals (Heikkila et al., 1972) . Propargylamines increase the expression of certain antioxidant enzymes, superoxide dismutase and catalase (Carillo et al., 1991 (Carillo et al., , 1994 . In our experiments the anti-oxidant capacity of HepG2 cells was enhanced by all doses of (-)-deprenyl and remarkably interesting that this increase of antioxidant capacity shows two peaks, one at 1 pM and one at 1 μΜ (-)-deprenyl treatment. Our results on HepG2 cells support that the antioxidant activity of (-)-deprenyl extends also to non-neural cells.
The role of estrogen on the onset and severity of neurodegenerative diseases is known as well as its potential role in neuroprotection (Brann et al., 2007) . This effect is mediated by its target molecule, the estrogen receptor. ER is a transcription factor that regulates the expression of several genes playing role in apoptosis, metabolism, or cell proliferation control.
Estrogens were proven to have neuroprotective action (Liu et al., 2010; Brown et al., 2009; Saldanha et al., 2009 ) mediated by any of the known ERs (Toran-Allerand, 2004).
In our experiments performed on an ER-positive cell line (-)-deprenyl treatment resulted in higher viability of serum-starved cell cultures. Although (-)-deprenyl does not have a chemically similar structure to estrogen we found that it was able to activate ER-dependent transcription. The E2-acivated ER also influences the expression of apoptotic enzymes (Brann et al., 2007) so the anti-apoptotic effect of (-)-deprenyl might be comparable to a Selective Estrogen Receptor Modulator-like activity. Direct activation of estrogen receptor with (-)-deprenyl treatment indicates that (-)-deprenyl is able to induce gene expression changes similar to estrogen.
In other words the survival of estrogen responsive MCF7 cells in serum-free cultures is supported as well as estrogen receptor mediated transcription is activated by (-)-deprenyl in these cells.
The results of our experiments neither support nor disprove of a direct relationship between the cytoptrotective, the antioxidant, the antiapoptotic and the ER-activating properties of -(-)deprenyl. However, our knowledge about these properties -which seem to be extended from neuroectodermal cells to cells of different origin -may be exploited in practice and broaden the pharmacological application of -(-) deprenyl. 
